CompletedEarly Phase 1

Reducing Health Disparity of Physical Functioning Among Young Adult Cancer Patients of Color

United States89 participantsStarted 2023-11-20

Plain-language summary

The purpose of the study is to pilot test of PAfitME™ among (1) young adults (YA) cancer patients of color (POC) (Analytic Sample \[N=36\] after attrition of 30%) and (2) YA cancer patients of White (POW) (Analytic Sample \[N=36\] after attrition of 30%). Aim 1: Evaluate Exergame Grading Scheme (EGS) validity when EGS is tested in relationship to standard lab tests (Bruce Treadmill Protocol and isometric/isokinetic dynamometry) and field fitness tests (6-minute walk test, handgrip, and Chair Stand Test). Aim 2a: Evaluate the feasibility (enrollment rate \[% of eligible patients\], attrition rate \[% in either intervention or control group\], adherence rate \[% of completed prescribed exergame minutes\]), safety (numbers of adverse events), and acceptability (satisfaction score \& exit qualitative interviews) of PAfitME™. Aim 2b: Evaluate the preliminary effect of 12-week PAfitME™ on cardiorespiratory fitness (6-minute walk test) and muscle strength (handgrip \[upper body\] and Chair Stand Test \[lower body\]) when compared with a usual care condition among YA cancer POC. Aim 2c: Evaluate the preliminary effect of 12-week PAfitME™ on cardiorespiratory fitness (6-minute walk test) and muscle strength (handgrip \[upper body\] and Chair Stand Test \[lower body\]) when compared with a usual care condition among YA cancer POW.

Who can participate

Age range

18 Years – 39 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. post-cancer treatment
. age of 18-39 years old
. ability to read and speak English
. medical clearance of stress test (Bruce treadmill protocol)
. no participation in an exercise program
. complaint of functional decline after cancer diagnoses
. complaint of fatigue or/and pain symptoms after cancer treatment.

Exclusion criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change 6-minute walk test

Timeframe: Baseline and Week 12

Trial details

NCT IDNCT07715344

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-14

View on ClinicalTrials.gov More Symptom Management trials